Comparative Pharmacology
Head-to-head clinical analysis: DAYTRANA versus DEXAMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYTRANA versus DEXAMPEX.
DAYTRANA vs DEXAMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
None Documented
None Documented
Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal.
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites.
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant